ArticleCancer immunology, immunotherapy : CII2026
Preclinical evaluation of rBCG-h12: an engineered Bacillus Calmette-Guérin with an enhanced activity against bladder and pancreatic cancers.
Chang-Ching Yeh et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.